18F NaF/18F FDG PET/MRI in Detecting Skeletal Metastases in Patients with Stage III-IV Breast Cancer or Stage II-IV Prostate Cancer

Status: complete

This clinical trial studies fluorine F 18 sodium fluoride (18F NaF)/fludeoxyglucose F-18 (18F FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in detecting skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. 18F NaF and 18F FDG are radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as PET/MRI. PET/MRI is a procedure that combines detailed pictures of areas inside the body from PET and MRI scans and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F NaF/18F FDG PET/MRI is better than standard imaging methods in detecting skeletal metastases.

Inclusion Criteria

Patient provides written informed consent
Patient is diagnosed with >= stage 3 breast cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10 micrograms/L), including patient with recurrent breast or prostate cancer
Patient is scheduled to undergo a conventional bone scan
Patient is capable of complying with study procedures
Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria

Patient is participating in other research protocols at the time of the NaF/FDG PETMRI scan
Patient is pregnant or nursing
Metallic implants (contraindicated for MRI)
Renal function impairment preventing administration of MRI contrast

PRIMARY OBJECTIVES:

I. Testing the hypothesis that the combined 18F NaF/18F FDG PET/MRI, either alone or in combination, provide improved diagnostic accuracy over 99mTc MDP (technetium tc-99m medronate) bone scanning.

SECONDARY OBJECTIVES:

I. Evaluating the combined 18F NaF/18F FDG PET/MRI as a reliable bone scanning modality.

II. Evaluating the performance and reliability of the proposed whole-body magnetic resonance imaging (WBMRI) sequences: IDEAL and enhanced diffusion weighted imaging (eDWI).

III. Evaluating a fast MRI protocol (2:30 min/bed).

OUTLINE:

Patients undergo a combined 18F NaF and 18F FDG PET/MRI scan over 45 minutes.

After completion of study, patients are followed up at 12 months.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.

18F NaF/18F FDG PET/MRI in Detecting Skeletal Metastases in Patients with Stage III-IV Breast Cancer or Stage II-IV Prostate Cancer

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help